SEC Form 4 · accession 0001615774-17-005170

Nabriva Therapeutics plc · NBRV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Table I — non-derivative securities

Table II — derivative securities

Explanation of responses

• F1These shares are owned directly by Vivo Hong Kong VIII, Co., Limited and Vivo Hong Kong Surplus VIII, Co., Limited, which are the record owners (together, the "Record Owners") of these shares. The Record Owners are wholly owned subsidiaries of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., respectively (together, the "Parents").
• F2Vivo Capital VIII, LLC is the general partner of the Parents and disclaims beneficial ownership over these shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. The voting members of Vivo Capital VIII, LLC are Dr. Frank Kung, Dr. Albert Cha, Dr. Edgar Engleman, Dr. Chen Yu, and Mr. Shan Fu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
• F3The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.60, inclusive. The reporting person undertakes to provide to Nabriva Therapeutics plc, any security holder of Nabriva Therapeutics plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.